Show simple item record

dc.contributor.authorFroghi, F
dc.contributor.authorSoggiu, F
dc.contributor.authorRicciardi, F
dc.contributor.authorGurusamy, K
dc.contributor.authorMartin, DS
dc.contributor.authorSingh, J
dc.contributor.authorSiddique, S
dc.contributor.authorEastgate, C
dc.contributor.authorCiaponi, M
dc.contributor.authorMcNeil, M
dc.contributor.authorFilipe, H
dc.contributor.authorSchwalowsky-Monks, O
dc.contributor.authorAsis, G
dc.contributor.authorVarcada, M
dc.contributor.authorDavidson, BR
dc.date.accessioned2020-07-09T13:16:59Z
dc.date.available2020-07-09T13:16:59Z
dc.date.issued2019-10
dc.identifier.issn2044-6055
dc.identifier.issn2044-6055
dc.identifier.otherARTN e028783
dc.identifier.urihttp://hdl.handle.net/10026.1/15934
dc.description.abstract

<jats:sec><jats:title>Introduction</jats:title><jats:p>Acute pancreatitis is an inflammatory disease of the pancreas with high risk of developing multiorgan failure and death. There are no effective pharmacological interventions used in current clinical practice. Maintaining fluid and electrolyte balance is the mainstay of supportive management. Goal-directed fluid therapy (GDFT) has been shown to decrease morbidity and mortality in surgical conditions with systemic inflammatory response. There is currently no randomised controlled trial (RCT) investigating the role of GDFT based on cardiac output parameters in patients with acute pancreatitis in the ward setting. A feasibility trial was designed to determine patient and clinician support for recruitment into an RCT of ward-based GDFT in acute pancreatitis, adherence to a GDFT protocol, safety, participant withdrawal, and to determine appropriate endpoints for a subsequent larger trial to evaluate efficacy.</jats:p></jats:sec><jats:sec><jats:title>Methods and analysis</jats:title><jats:p>The GDFT in Acute Pancreatitis trial is a prospective two-centre feasibility RCT. Eligible adults admitted with new onset of acute pancreatitis will be enrolled and randomised into ward-based GDFT (n=25) or standard fluid therapy (n=25) within 6 hours from the diagnosis and continuing for the following 48 hours. Cardiac output parameters will be monitored with a non-invasive device (Cheetah NICOM; Cheetah Medical). The intervention group will consist of a protocolised GDFT approach consisting of stroke volume optimisation with crystalloid fluid boluses, while the control group will receive standard care fluid therapy as advised by the clinical team. The primary endpoint is feasibility. Secondary endpoints will include safety of the intervention, complications, mortality, admission to intensive care unit, cost and quality of life.</jats:p></jats:sec><jats:sec><jats:title>Ethics and dissemination</jats:title><jats:p>Ethics approval was granted by the London Central Research Ethics Committee (17/LO/1235, project ID: 221872). The results of this trial will be presented to international conference with interest in general surgery and acute care and published in a peer-reviewed journal.</jats:p></jats:sec><jats:sec><jats:title>Trial registration number</jats:title><jats:p><jats:ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="ISRCTN36077283">ISRCTN36077283</jats:ext-link>.</jats:p></jats:sec>

dc.format.extente028783-e028783
dc.format.mediumElectronic
dc.languageen
dc.language.isoen
dc.publisherBMJ
dc.subjectacute pancreatitis
dc.subjectcardiac output
dc.subjectfluid therapy
dc.subjectgoal-directed fluid therapy
dc.subjectAcute Disease
dc.subjectAdult
dc.subjectFeasibility Studies
dc.subjectFluid Therapy
dc.subjectHumans
dc.subjectMulticenter Studies as Topic
dc.subjectPancreatitis
dc.subjectProspective Studies
dc.subjectRandomized Controlled Trials as Topic
dc.titleWard-based Goal-Directed Fluid Therapy (GDFT) in Acute Pancreatitis (GAP) trial: study protocol for a feasibility randomised controlled trial
dc.typejournal-article
dc.typeArticle
plymouth.author-urlhttps://www.ncbi.nlm.nih.gov/pubmed/31601585
plymouth.issue10
plymouth.volume9
plymouth.publication-statusPublished
plymouth.journalBMJ Open
dc.identifier.doi10.1136/bmjopen-2018-028783
plymouth.organisational-group/Plymouth
plymouth.organisational-group/Plymouth/Faculty of Health
plymouth.organisational-group/Plymouth/Faculty of Health/Peninsula Medical School
plymouth.organisational-group/Plymouth/REF 2021 Researchers by UoA
plymouth.organisational-group/Plymouth/REF 2021 Researchers by UoA/UoA01 Clinical Medicine
plymouth.organisational-group/Plymouth/Users by role
plymouth.organisational-group/Plymouth/Users by role/Academics
dc.publisher.placeEngland
dcterms.dateAccepted2019-09-13
dc.rights.embargodate2020-7-16
dc.identifier.eissn2044-6055
dc.rights.embargoperiodNot known
rioxxterms.versionofrecord10.1136/bmjopen-2018-028783
rioxxterms.licenseref.urihttp://www.rioxx.net/licenses/all-rights-reserved
rioxxterms.licenseref.startdate2019-10
rioxxterms.typeJournal Article/Review


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record


All items in PEARL are protected by copyright law.
Author manuscripts deposited to comply with open access mandates are made available in accordance with publisher policies. Please cite only the published version using the details provided on the item record or document. In the absence of an open licence (e.g. Creative Commons), permissions for further reuse of content should be sought from the publisher or author.
Theme by 
Atmire NV